Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 504

1.

Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.

Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE.

J Hypertens. 2014 Nov;32(11):2267-76; discussion 2276. doi: 10.1097/HJH.0000000000000313.

PMID:
25275251
[PubMed - in process]
2.

Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.

Imbalzano E, Scarpelli M, Mandraffino G, Creazzo M, Lizio G, Trapani G, Dattilo G, Dalbeni A, Tomasello C, Sardo MA, Saitta A.

J Renin Angiotensin Aldosterone Syst. 2014 Jul 27. pii: 1470320314530018. [Epub ahead of print]

PMID:
25070350
[PubMed - as supplied by publisher]
3.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

PMID:
24936255
[PubMed]
Free PMC Article
4.
5.

Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan.

Makhlough A, Kashi Z, Akha O, Zaboli E, Yazdanicharati J.

Nephrourol Mon. 2014 Jan 14;6(1):e12148. doi: 10.5812/numonthly.12148. eCollection 2014 Jan.

PMID:
24719811
[PubMed]
Free PMC Article
6.

Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.

Armanini D, Sabbadin C, Donà G, Clari G, Bordin L.

Expert Opin Pharmacother. 2014 May;15(7):909-12. doi: 10.1517/14656566.2014.896901. Epub 2014 Mar 11.

PMID:
24617854
[PubMed - indexed for MEDLINE]
7.

Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.

Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, Glasziou P, Neil A, Dunger D, M Colhoun H, Pugh C, Wong G, Perera R, Shine B.

Health Technol Assess. 2014 Feb;18(14):1-128. doi: 10.3310/hta18140. Review.

PMID:
24576414
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

The role of adiponectin in renal physiology and development of albuminuria.

Christou GA, Kiortsis DN.

J Endocrinol. 2014 May 12;221(2):R49-61. doi: 10.1530/JOE-13-0578. Print 2014 May. Review.

PMID:
24464020
[PubMed - indexed for MEDLINE]
Free Article
10.

Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?

Vivian E, Mannebach C.

Drugs Context. 2013 Mar 27;2013:212249. doi: 10.7573/dic.212249. eCollection 2013 Mar 27. Review.

PMID:
24432038
[PubMed]
Free PMC Article
11.

Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study.

Kung K, Chow KM, Hui EM, Leung M, Leung SY, Szeto CC, Lam A, Li PK.

BMC Fam Pract. 2014 Jan 10;15:8. doi: 10.1186/1471-2296-15-8.

PMID:
24410810
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Effects of different antihypertensive strategies on reversing urinary albumin excretion].

Wang HY, Sun NL, Chen YY, Ma ZY, Xi Y, Wang LY, Yang F.

Zhonghua Yi Xue Za Zhi. 2013 Sep 17;93(35):2810-2. Chinese.

PMID:
24360178
[PubMed - indexed for MEDLINE]
13.

Current practices in the management of diabetic nephropathy.

Chan G, Tang SC.

J R Coll Physicians Edinb. 2013;43(4):330-2; quiz 333. doi: 10.4997/JRCPE.2013.413. Review.

PMID:
24350318
[PubMed - indexed for MEDLINE]
14.

Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers.

Graham DJ, Zhou EH, McKean S, Levenson M, Calia K, Gelperin K, Ding X, MaCurdy TE, Worrall C, Kelman JA.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):331-9. doi: 10.1002/pds.3548. Epub 2013 Nov 26.

PMID:
24277678
[PubMed - in process]
15.

Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease.

Futrakul N, Futrakul P.

World J Nephrol. 2013 Nov 6;2(4):125-8. doi: 10.5527/wjn.v2.i4.125. Review.

PMID:
24255895
[PubMed]
Free PMC Article
16.

Lowering effect of valsartan on fetuin-A in type 1 diabetes mellitus.

Gheissari A, Javanmard SH, Shirzadi R, Amini M, Khalili N.

Iran J Kidney Dis. 2013 Nov;7(6):440-5.

PMID:
24241089
[PubMed - indexed for MEDLINE]
Free Article
17.

Impaired endocytosis in proximal tubule from subchronic exposure to cadmium involves angiotensin II type 1 and cubilin receptors.

Santoyo-Sánchez MP, Pedraza-Chaverri J, Molina-Jijón E, Arreola-Mendoza L, Rodríguez-Muñoz R, Barbier OC.

BMC Nephrol. 2013 Oct 5;14:211. doi: 10.1186/1471-2369-14-211.

PMID:
24093454
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Albuminuria in the diabetic patient: practical management].

Kistler AD.

Praxis (Bern 1994). 2013 Oct 2;102(20):1229-35. doi: 10.1024/1661-8157/a001429. Review. German.

PMID:
24088233
[PubMed - indexed for MEDLINE]
19.

Microalbuminuria and hypertension in pregnancy: role of aldosterone and inflammation.

Armanini D, Ambrosini G, Sabbadin C, Donà G, Clari G, Bordin L.

J Clin Hypertens (Greenwich). 2013 Sep;15(9):612-4. doi: 10.1111/jch.12135. Epub 2013 May 31.

PMID:
24034651
[PubMed - indexed for MEDLINE]
20.

Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study.

Brown JM, Secinaro K, Williams JS, Vaidya A.

BMC Endocr Disord. 2013 Aug 23;13:33. doi: 10.1186/1472-6823-13-33.

PMID:
23971740
[PubMed]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk